The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

An Australian-first study demonstrating the effectiveness of a new immunization against respiratory syncytial virus ... Center of Vaccines and Infectious Diseases and Perth Children's Hospital ...

where vaccine efficacy is already demonstrated. Following this latest approval, Abrysvo has become the first and only RSV vaccine approved for use in non-pregnant adults under 50 years of age in ...

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster presented here.These data were presented at the 2025 American Academy of ...

“With an indication that also includes pregnant individuals between weeks 24 and 36 gestation to help protect infants ... et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

This includes ABRYSVO® (Respiratory Syncytial Virus ... RSV vaccines, covering older adults, adults 18 and older at heightened risk of severe disease, and pregnant women to help protect infants.” ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV ... in order to protect their babies after birth found that the vaccine had efficacy of 81.8% in preventing lower ...

This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine ... (RSV-LRTD), as well as infants through maternal immunization. ABRYSVO is an unadjuvanted, bivalent vaccine that was designed ...